22722 29TH DR. SE, SEATTLE, WA
Market cap: $232.1M (2/09/2026)
Price: $4.36
Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Announces Pricing of $45.0 Million Underwritten Public Offering
Submission of Matters to a Vote of Security Holders
Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
Annual Report to Security Holders
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement